Project Grant R16AI192040
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $400,125 Project Grant to Meharry Medical College under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate a novel mechanism by which HIV-1 evades the APOBEC3G antiviral function through selective viral RNA packaging. The research aims to: 1) compare APOBEC3G-related mutation profiles in infected cells and viral particles, focusing on key RNA packaging elements, and 2) investigate the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $859,992 Project Grant to Yale University for the "Molecular Investigations of HIV-1 Maturation Pathways and Inhibitor Actions in situ" research project. The grant, funded under NIAID's Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to use advanced in-situ cryo-electron microscopy and tomography techniques to visualize the structural transitions of the HIV-1 virus during the maturation...
- This $109,671 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the mechanisms by which HIV-infected macrophages evade natural killer (NK) cell-mediated killing. The central hypothesis is that HIV-infected macrophages resist NK cell-mediated killing by reducing NK cell lytic function and antagonizing death receptor signaling. The specific aims are to: 1) Characterize the release of...
- This $243,713 Project Grant awarded on January 27, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research to characterize mechanisms by which HIV-infected macrophages evade antibody-dependent cell-mediated cytotoxicity (ADCC) by natural killer (NK) cells. The objective is to determine how infected macrophages, which serve as a physiologically relevant viral reservoir, resist NK cell...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $653,693 Project Grant to Emory University to conduct structural investigations of the HIV-1 virion and the mechanism of the capsid targeting compound lenacapavir. The research aims to leverage advanced cryo-electron microscopy and tomography techniques to study the structural details of immature HIV-1 assembly and the mechanistic...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- This $650,934 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports a mechanistic study of how the HIV Gag protein interacts with and sequesters the CARD8 inflammasome, a cellular component that can trigger the death of HIV-infected cells. The goal is to develop a detailed molecular understanding of this interaction, which could inform new strategies for...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This federal Project Grant award of $848,839 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover new mechanisms by which HIV accessory proteins control natural killer (NK) cell function. The research aims to identify new NK cell ligands regulated by HIV infection and examine how changes to HIV accessory proteins like Nef and Vif impact the "missing self" trigger that drives NK cell...
- The University of Chicago was awarded a $295,276 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to develop a mechanistic understanding of viral assembly, maturation, and uncoating processes, which could aid in the design of new antiretroviral therapies targeting...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program, will provide $145,500 to Meharry Medical College to study the mechanisms by which the lysosome modulating compound bafilomycin A1 inhibits HIV-1 replication. The goal is to understand the role of the lysosomal pathway in the HIV-1 life cycle. Preliminary results indicate that bafilomycin A1, as well as other lysosome modulators, can inhibit HIV-1 replication, with bafilomycin A1 showing the most potent effect. The research will investigate how bafilomycin A1-induced changes to lysosomes, including cholesterol accumulation and positioning, impact the HIV-1 replication process. The award began on Aug 11, 2025 and is scheduled for completion on Jul 31, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $145.5k | 8/11/25 |